Patents by Inventor Gregory Alan Lazar

Gregory Alan Lazar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fc variants with altered binding to FcRn
    Patent number: 8883973
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: November 11, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Optimized Fc variants and methods for their generation
    Patent number: 8858937
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: October 14, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Fc variants with altered binding to FcRn
    Patent number: 8852586
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: October 7, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • FC VARIANTS THAT IMPROVE FCRN BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
    Publication number: 20140294812
    Abstract: The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 2, 2014
    Applicant: Xencor, Inc.
    Inventor: Gregory Alan Lazar
  • Optimized Fc variants and methods for their generation
    Patent number: 8809503
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: August 19, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Optimized Fc variants
    Patent number: 8802823
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: August 12, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Fc variants with altered binding to FcRn
    Patent number: 8802820
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: August 12, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John Rudolph Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Optimized Fc variants
    Patent number: 8753629
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: June 17, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Fc variants
    Patent number: 8753628
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: June 17, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • ENGINEERED IMMUNOGLOBULINS WITH EXTENDED IN VIVO HALF-LIFE
    Publication number: 20140161790
    Abstract: The present application relates to immunoglobulin compositions with improved half-life, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: November 19, 2013
    Publication date: June 12, 2014
    Applicant: Xencor, Inc.
    Inventors: John Desjarlais, Gregory Alan Lazar
  • Fc variants having increased affinity for fcyrllc
    Patent number: 8735545
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: May 27, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Fc Variants
    Patent number: 8735547
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: May 27, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized fc variants and methods for their generation
    Patent number: 8734791
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: May 27, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Optimized Antibodies That Target CD19
    Publication number: 20140112916
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: September 10, 2013
    Publication date: April 24, 2014
    Applicant: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Optimized Antibodies That Target CD19
    Publication number: 20140086906
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: August 5, 2013
    Publication date: March 27, 2014
    Applicant: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • OPTIMIZED Fc VARIANTS
    Publication number: 20140073768
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: November 12, 2013
    Publication date: March 13, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Fc Variants
    Publication number: 20130302315
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: June 14, 2013
    Publication date: November 14, 2013
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Fc Variants
    Publication number: 20130273043
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: June 11, 2013
    Publication date: October 17, 2013
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells
    Patent number: 8551485
    Abstract: The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: October 8, 2013
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, Eugene Alexander Zhukovsky
  • Optimized Fc Variants
    Publication number: 20130261289
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: April 25, 2013
    Publication date: October 3, 2013
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter